The pharmacokinetics of telaprevir and selected antiretroviral medications in HCV/HIV co-infected patients

Trial Profile

The pharmacokinetics of telaprevir and selected antiretroviral medications in HCV/HIV co-infected patients

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2012

At a glance

  • Drugs Telaprevir (Primary) ; Antiretrovirals; Atazanavir/ritonavir; Efavirenz; Peginterferon; Ribavirin
  • Indications Hepatitis C; HIV infections
  • Focus Pharmacokinetics
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 25 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top